More From This User
Related Docuements
Pharmacoeconomic Analysis in R&D Decision Making
This report gives in depth analysis of the ways in which the pharmaceutical i...
From linda3395
Doug GrantSVP & Head, Corporate Affairs
The Challenge of Reimbursement The Challenge of Reimbursement
R
eimbursement decision-making for newmedications is changing rapidly
Increasing influence of health technology assessment(HTA) agencies and the associated complexity of formulary reviews, both locally and internationallyThe emergence of payer demands for ³risk-sharing´deals and pricing concessions to reduce drug plan costgrowthGlobal downturn has exacerbated these trendsAt the same time, internally we are faced with the realityof global pricing imperatives and country launchsequencing considerations
E
volution -
R
eimbursement
E
nvironment
1970¶s1990¶s1980¶s2000¶s2010 and beyond
Traditional Model
-market themedication aggressively todoctors after NoC
Cost-conscious Model
-provideclinical data to supportreimbursement
Cost-constrained Model
-provide clinicaland economic data to justify use of themedication as part of the therapeutic mix
Cost-containment Model
-workhard to differentiate themedicine from alternatives
Negotiation Model
of 00
The Challenge of Reimbursement
92 Reads
Info and Rating
| Category: | Uncategorized. |
| Rating: | |
| Upload Date: | 06/28/2011 |
| Copyright: | Attribution Non-commercial |
| Tags: |
Leave a Comment